Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer
Article in Frontiers in Immunology (January 2024)
The most recent citing publications are shown below. View all 12 publications that cite this research output on Dimensions.
Article in Frontiers in Immunology (January 2024)
Article in BMJ Global Health (November 2023)
Article in Journal of Global Health (November 2023)